Effectiveness of lenalidomide in relapsed primary cutaneous diffuse large B-cell lymphoma, leg type.
Détails
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_19B6596F010F
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Institution
Titre
Effectiveness of lenalidomide in relapsed primary cutaneous diffuse large B-cell lymphoma, leg type.
Périodique
Clinical case reports
ISSN
2050-0904 (Print)
ISSN-L
2050-0904
Statut éditorial
Publié
Date de publication
05/2019
Peer-reviewed
Oui
Volume
7
Numéro
5
Pages
964-967
Langue
anglais
Notes
Publication types: Case Reports
Publication Status: epublish
Publication Status: epublish
Résumé
The primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) has a poor prognosis. R-CHOP with or without radiotherapy is the available recommendations for first-line treatment. Relapses/refractory cases are frequent with no standardized therapeutic guidelines. Lenalidomide seems to be an excellent therapeutic option as a second-line treatment of relapsed PCDLBCL-LT.
Mots-clé
chemotherapy, leg type, lenalidomide, primary cutaneous diffuse large B‐cell lymphoma
Pubmed
Web of science
Open Access
Oui
Création de la notice
25/05/2019 11:40
Dernière modification de la notice
15/01/2021 8:08
Données d'usage
